Table 1

T-Cell receptor status and CD26 expression and in vitro effects of 2′-deoxycoformycin (dCF) in primary T-cell malignancies

Patient no.DiagnosisT-cell receptorSource of tumor cellsCD26 expression (% of positive cells)% growth inhibitiona
αβγδ
1T-LBLb+BM1ND
2T-LBL±PB5545
3T-LBL+BM14ND
4T-LBLBM195
5T-LBL+BM978
6T-LBL+PB1 (90)c90 (35)c
7PTCL+PB10ND
8PTCL+PB8023
9HSL+PB195
10HSL+PB190
11HSL+PB11ND
  • a Tumor cells (2.0 × 105 cells/ml) from bone marrow (BM) or peripheral blood (PB) samples were cultured in semisolid medium in the presence of dCF (100 μM) and 2′-deoxyadenosine (dAdo) (10 μm). After 14 days, plates were observed under phase contrast microscopy, and aggregates with ≥40 cells were scored as colonies. Data are reported as % of growth inhibition referred to controls performed with dAdo (10 μm) alone.

  • b T-LBL, lymphoblastic lymphoma; ND, not determined; PTCL, peripheral T-cell lymphoma; HSL, hepatosplenic γδ T-cell lymphoma.

  • c Figures in parenthesis refer to CD26 expression and growth inhibition by circulating blast cells of patient #6 at relapse.